Literature DB >> 10378623

Idiopathic nonhistaminergic angioedema.

M Cicardi1, L Bergamaschini, L C Zingale, D Gioffré, A Agostoni.   

Abstract

PURPOSE: We sought to describe the characteristics of a group of patients with idiopathic nonhistaminergic angioedema and their response to prophylactic treatment with tranexamic acid.
METHODS: We identified 25 patients (15 men and 10 women; age at diagnosis 16 to 77 years) who had idiopathic nonurticarial angioedema that was not prevented by histamine-1 (H1) blockers. Known causes of angioedema were excluded by clinical history, physical examination, and diagnostic tests.
RESULTS: The median age at the onset of symptoms was 35 years (range 8 to 66). The frequency of attacks was > 12 per year for 16 patients, six to 11 per year for 6 patients, and one to five per year for 3 patients. All patients had cutaneous attacks, 13 (52%) reported swellings of the pharynx or larynx, and 5 (20%) had symptoms consistent with bowel angioedema. Because of the similarities between these patients and patients who are deficient in C1 inhibitor, the 15 patients with severe and frequent attacks were started on prophylactic treatment with the antifibrinolytic agent tranexamic acid, 1 g three times a day orally for 3 months, tapered according to its effectiveness. The symptoms of 11 patients decreased to less than one attack per year, and the remaining 4 patients had partial remissions (less than 4 attacks per year). Fourteen patients are still being treated with tranexamic acid.
CONCLUSION: Patients with idiopathic nonhistaminergic angioedema appear to have similar clinical features and response to treatment with tranexamic acid as those who are deficient in C1 inhibitor. This suggests that those two forms of angioedema might have, at least in part, a similar pathogenesis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10378623     DOI: 10.1016/s0002-9343(99)00123-0

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  18 in total

1.  Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond.

Authors:  Angelo Agostoni; Emel Aygören-Pürsün; Karen E Binkley; Alvaro Blanch; Konrad Bork; Laurence Bouillet; Christoph Bucher; Anthony J Castaldo; Marco Cicardi; Alvin E Davis; Caterina De Carolis; Christian Drouet; Christiane Duponchel; Henriette Farkas; Kálmán Fáy; Béla Fekete; Bettina Fischer; Luigi Fontana; George Füst; Roberto Giacomelli; Albrecht Gröner; C Erik Hack; George Harmat; John Jakenfelds; Mathias Juers; Lajos Kalmár; Pál N Kaposi; István Karádi; Arianna Kitzinger; Tímea Kollár; Wolfhart Kreuz; Peter Lakatos; Hilary J Longhurst; Margarita Lopez-Trascasa; Inmaculada Martinez-Saguer; Nicole Monnier; István Nagy; Eva Németh; Erik Waage Nielsen; Jan H Nuijens; Caroline O'grady; Emanuela Pappalardo; Vincenzo Penna; Carlo Perricone; Roberto Perricone; Ursula Rauch; Olga Roche; Eva Rusicke; Peter J Späth; George Szendei; Edit Takács; Attila Tordai; Lennart Truedsson; Lilian Varga; Beáta Visy; Kayla Williams; Andrea Zanichelli; Lorenza Zingale
Journal:  J Allergy Clin Immunol       Date:  2004-09       Impact factor: 10.793

Review 2.  Activation of blood coagulation in chronic urticaria: pathophysiological and clinical implications.

Authors:  Massimo Cugno; Angelo V Marzano; Riccardo Asero; Alberto Tedeschi
Journal:  Intern Emerg Med       Date:  2009-12-01       Impact factor: 3.397

Review 3.  Hereditary angioedema in childhood: an approach to management.

Authors:  Didier G Ebo; Marjoke M Verweij; Kathleen J De Knop; Margo M Hagendorens; Chris H Bridts; Luc S De Clerck; Wim J Stevens
Journal:  Paediatr Drugs       Date:  2010-08-01       Impact factor: 3.022

4.  Angioedema without urticaria: a large clinical survey.

Authors:  Lorenza C Zingale; Laura Beltrami; Andrea Zanichelli; Lorena Maggioni; Emanuela Pappalardo; Benedetta Cicardi; Marco Cicardi
Journal:  CMAJ       Date:  2006-10-24       Impact factor: 8.262

5.  Increased activity of coagulation factor XII (Hageman factor) causes hereditary angioedema type III.

Authors:  Sven Cichon; Ludovic Martin; Hans Christian Hennies; Felicitas Müller; Karen Van Driessche; Anna Karpushova; Wim Stevens; Roberto Colombo; Thomas Renné; Christian Drouet; Konrad Bork; Markus M Nöthen
Journal:  Am J Hum Genet       Date:  2006-10-18       Impact factor: 11.025

6.  Hereditary angioedema with normal c1 inhibition.

Authors:  Konrad Bork
Journal:  Curr Allergy Asthma Rep       Date:  2009-07       Impact factor: 4.806

Review 7.  Angioedema Phenotypes: Disease Expression and Classification.

Authors:  Maddalena Alessandra Wu; Francesca Perego; Andrea Zanichelli; Marco Cicardi
Journal:  Clin Rev Allergy Immunol       Date:  2016-10       Impact factor: 8.667

8.  Tranexamic acid as maintenance treatment for non-histaminergic angioedema: analysis of efficacy and safety in 37 patients.

Authors:  C Wintenberger; I Boccon-Gibod; D Launay; O Fain; G Kanny; P Y Jeandel; L Martin; A Gompel; L Bouillet
Journal:  Clin Exp Immunol       Date:  2014-10       Impact factor: 4.330

Review 9.  Differential Diagnosis and Management Issues of Idiopathic Angiooedema and their Resolution.

Authors:  Andrea Zanichelli; Marta Mansi; Maddalena A Wu; Giulia Azin; Marco Cicardi
Journal:  J Crit Care Med (Targu Mures)       Date:  2015-06-05

10.  Angioedema.

Authors:  Allen P Kaplan
Journal:  World Allergy Organ J       Date:  2008-06       Impact factor: 4.084

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.